top of page
Search

Heart hope as potential funnel-web venom drug enters clinical trial

  • University of Queensland
  • Jan 8
  • 1 min read

A potential treatment for heart attack and stroke, derived from a spider venom molecule identified by University of Queensland researchers, has been administered to the first participants in a clinical trial.


The phase 1 study, currently underway, will assess the safety, tolerability and dosage of IB409, a novel drug developed by Brisbane-based biotechnology company Infensa Bioscience.


Professor Glenn King from UQ’s Institute for Molecular Bioscience said his team had published ‘exceptionally promising’ preclinical results with a protein, called Hi1a, derived from the venom of a  K’gari funnel web spider.


Read the full article on UQ News.


Professor Nathan Palpant, Professor Mark Smythe and Professor Glenn King. 
Professor Nathan Palpant, Professor Mark Smythe and Professor Glenn King. 

(Photo credit: The University of Queensland. )



 
 
bottom of page